Angioedema induced by angiotensin-converting enzyme inhibitors
Authors:
- Paloma CampoPCPaloma Campo
- Tahía D. FernandezTahía D. Fernandez
- Gabriela CantoGCGabriela Canto
- Cristobalina MayorgaCMCristobalina Mayorga
- 1 August 2013
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Allergy and Clinical Immunology
- Vol. 13 (4) , 337-344
Abstract
Since angiotensin-converting enzyme inhibitors (ACEIs) were first introduced in the 1980s for treatment of hypertension and congestive heart failure, there has been progressive increase in use due to these and other new indications. This fact has led to a parallel increase in adverse effects induced by ACEIs, mainly angioedema, with different degrees of severity. Different studies indicate that ACEI-induced angioedema is associated with high levels of bradykinin of different origin and this preferentially occurs in females and in African-American populations. The diagnosis of ACEI-induced angioedema can be difficult, due to its variable latency period from the initiation of treatment. Differential diagnosis of other causes of angioedema must be considered. The management of ACEI-induced angioedema involves the withdrawal of the causative drug and the treatment of the reaction with different drugs depending on its severity. Some studies have shown that angiotensin II receptor blockers (ARBs) may be an alternative, although some patients (<10%) with ACEI-associated angioedema also develop angioedema episodes after ARB intake. Therefore, ARBs may be reserved for patients with high therapeutic need for angiotensin inhibition. The present review will focus on current and relevant aspects of ACEI-induced angioedema. The pathological mechanism, epidemiology and risk factors, differential diagnosis, patient management and treatment will be discussed.Keywords
This publication has 84 references indexed in Scilit:
- Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedemaInternational Journal of Emergency Medicine, 2012
- Angiotensin-Converting Enzyme (ACE) Gene Insertion/Deletion Polymorphism and ACE Inhibitor-Related Cough: A Meta-AnalysisPLOS ONE, 2012
- Ecallantide in Acute Hereditary Angioedema†BioDrugs, 2011
- Treatment of angiotensin-converting enzyme inhibitor–related angioedema with the bradykinin B2 receptor antagonist icatibantJournal of the American Academy of Dermatology, 2010
- 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedemaAllergy, Asthma & Clinical Immunology, 2010
- HAE therapies: past present and futureAllergy, Asthma & Clinical Immunology, 2010
- Hereditary angioedema in womenAllergy, Asthma & Clinical Immunology, 2010
- Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With HypertensionThe Journal of Clinical Hypertension, 2010
- Dipeptidyl Peptidase IV in Angiotensin-Converting Enzyme Inhibitor–Associated AngioedemaHypertension, 2008
- Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedemaAnnals of Allergy, Asthma & Immunology, 2004